Skip to main content
SpringerLink
Log in

Percutaneous Coronary Intervention in Diabetics

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eschwege E, Simon D, Balkau B. The growing burden of diabetes in the world population. International Diabetes Federation Bulletin 1997;42:14-19.

    Google Scholar 

  2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431.

    Google Scholar 

  3. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, Thompson TJ. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the US. Diabetes Care 2001;24:1936-1940.

    Google Scholar 

  4. Butler RN. Population aging and health. BMJ 1997;315:1082-1084.

    Google Scholar 

  5. Kunugi T. Women and population aging. Asia Pac Pop J 1989;4:75-79.

    Google Scholar 

  6. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-211.

    Google Scholar 

  7. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: Prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998;22:39-47.

    Google Scholar 

  8. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;9(Suppl 4):228S-233S.

    Google Scholar 

  9. Popkin BM, Horton S, Kim S, Mahal A, Shuigao J. Trends in diet, nutritional status, and diet-related non-communicable diseases in China and India: The economic costs of the nutrition transition. Nutr Rev 2001;59:379-390.

    Google Scholar 

  10. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20–74 years. Diabetes 1987;36:523-534.

    Google Scholar 

  11. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;2:434-444.

    Google Scholar 

  12. Association AD. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989;12:573-579.

    Google Scholar 

  13. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.

    Google Scholar 

  14. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris M, ed. Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 1995:429-448.

    Google Scholar 

  15. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin dependent diabetes. In: Harris M, ed. Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 1995:233-255.

    Google Scholar 

  16. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.

    Google Scholar 

  17. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997;126:296-306.

    Google Scholar 

  18. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO-IIb investigators. Eur Heart J 2000;21:1750-1758.

    Google Scholar 

  19. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-1019.

    Google Scholar 

  20. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Lancet 1994;343:311-322.

    Google Scholar 

  21. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-925.

    Google Scholar 

  22. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-179.

    Google Scholar 

  23. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. JAMA 1988;260:3456-3460.

    Google Scholar 

  24. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984;108:31-37.

    Google Scholar 

  25. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T; The MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.

    Google Scholar 

  26. Sprafka JM, Burke GI, Folsom AR, McGovern PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: The Minnesota Heart Survey. Diabetes Care 1991;14:537-543.

    Google Scholar 

  27. Parisi AF, Folland ED, Hartigan P, A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-16.

    Google Scholar 

  28. Folland ED, Hartigan PM, Parisi AF, Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: Outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. J Am Coll Cardiol 1997;29:1505-1511.

    Google Scholar 

  29. RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina: The Second Randomized Intervention Treatment of Angina (RITA-2) trial. Lancet 1997;350:461.

    Google Scholar 

  30. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical therapy for non-acute coronary heart disease: Meta-analysis of randomized trials. BMJ 2000;321:73.

    Google Scholar 

  31. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)—Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.

    Google Scholar 

  32. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. GUSTO IIb investigators. N Engl J Med 1997;336:1621-1628.

  33. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-679.

    Google Scholar 

  34. Detre K, Holubkov R, Kelsey S, Cowley M, Kent K, Williams D, Myler R, Faxon D, Holmes D Jr, Bourassa M, Block P, Cosselin A, Bentivoglio L, Leatherman L, Dorros G, King S III, Galichia J, Al Bassam M, Leon M, Robertson T, Passamani E. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988;318:265-270.

    Google Scholar 

  35. Anderson HV, Shaw RE, Brindis RG, Hewitt K, Krone RJ, Block PC, McKay CR, Weintraub WS. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002;39:1096-1103.

    Google Scholar 

  36. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-1825.

    Google Scholar 

  37. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS Jr, Morris DC, King SB 3rd. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-989.

    Google Scholar 

  38. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-928.

    Google Scholar 

  39. Gowda MS, Vacek JL, Hallas D. One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1998;81:1067-1071.

    Google Scholar 

  40. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551-2556.

    Google Scholar 

  41. Halon DA, Merdler A, Flugelman MY, Shifroni G, Khader N, Shiran A, Shahla J, Lewis BS. Importance of diabetes mellitus and systemic hypertension rather than completeness of revascularization in determining long-term outcome after coronary balloon angioplasty (the LDCMC registry). Lady Davis Carmel Medical Center. Am J Cardiol 1998;82:547-553.

    Google Scholar 

  42. Levine GN, Jacobs AK, Keeler GP, Whitlow PL, Berdan LG, Leya F, Topol EJ, Califf RM. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). Coronary Angioplasty Versus Excisional Atherectomy Trial Investigators. Am J Cardiol 1997;79:748-755.

    Google Scholar 

  43. Myler RK, Topol EJ, Shaw RE, Stertzer SH, Clark DA, Fishman J, Murphy MC. Multiple vessel coronary angioplasty: Classification, results, and patterns of restenosis in 494 consecutive patients. Cathet Cardiovasc Diagn 1987;13:1-15.

    Google Scholar 

  44. Holmes DR Jr., Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77C-81C.

    Google Scholar 

  45. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, Block PC, Shaw LJ, Hewitt K, Weintraub WS. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998–2000. J Am Coll Cardiol 2002;39:1104-1112.

    Google Scholar 

  46. Reginelli JP, Bhatt DL. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology. J Invas Cardiol 2002;14:2E-11E.

    Google Scholar 

  47. Ellis SG, Narins CR. Problem of angioplasty in diabetes. Circulation 1997;96:1707-1710.

    Google Scholar 

  48. Marso SP, Giorgi LV, Johnson WL, Huber KC, Laster SB, Shelton CJ, McCallister BD, Coen MM, Rutherford BD. Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital mortality following percutaneous coronary intervention: An analysis of 25,223 patients over 20 years. Am Heart J 2003;145:270-277.

    Google Scholar 

  49. Fuchs S, Stabile E, Kinnaird TD, Mintz GS, Gruberg L, Canos DA, Pinnow EE, Kornowski R, Suddath WO, Satler LF, Pichard AD, Kent KM, Weissman NJ. Stroke complicating percutaneous coronary interventions; incidence, predictors, and prognostic implications. Circulation 2002;106:86-91.

    Google Scholar 

  50. Akkerhuis KM, Deckers JW, Lincoff AM, Tcheng JE, Boersma E, Anderson K, Balog C, Califf RM, Topol EJ, Simoons ML. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA 2001;286:78-82.

    Google Scholar 

  51. Weintraub WS, Kosinski AS, Brown CL 3rd, King SB 3rd. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol 1993;21:6-14.

    Google Scholar 

  52. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S. Ellis S, Rake R, Goldberg S. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.

    Google Scholar 

  53. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.

    Google Scholar 

  54. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-589.

    Google Scholar 

  55. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-1873.

    Google Scholar 

  56. Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET investigators. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002;105:2730-2736.

    Google Scholar 

  57. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: A controlled study. J Am Coll Cardiol 2000;35:1554-1559.

    Google Scholar 

  58. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-1436.

    Google Scholar 

  59. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: A serial intravascular ultrasound study. Circulation 1997;95:1366-1369.

    Google Scholar 

  60. Iwase E, Tawata M, Aida K, Ozaki Y, Kume S, Satoh K, Qi R, Onaya T. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. Metabolism 1998;47:699-705.

    Google Scholar 

  61. Knobler H, Savion M, Shenkman B, Kotev-Emeth S, Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998;90:181-190.

    Google Scholar 

  62. Tschoepe D, Roesen P. Heart disease in diabetes mellitus: A challenge for early diagnosis and intervention. Exp Clin Endocrinol Diabetes 1998;106:16-24.

    Google Scholar 

  63. Tschoepe D, Driesch E, Schwippert B, Lampeter EF. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia 1997;40:573-577.

    Google Scholar 

  64. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990;20:166-170.

    Google Scholar 

  65. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-535.

    Google Scholar 

  66. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, Gries FA. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991;17:433-438.

    Google Scholar 

  67. Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S, Wagner OF, Eichler HG. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 1996;76:328-332.

    Google Scholar 

  68. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte cross-talk in diabetes mellitus. Horm Metab Res 1997;29:631-635.

    Google Scholar 

  69. Park SH, Marso SP, Forudi F, Lincoff AM. Diabetes and the response to arterial injury (abstr). Circulation 1998;98:I-8.

    Google Scholar 

  70. Akasaka T, Yoshida K, Hozumi T, Takagi T, Kaji S, Kawamoto T, Morioka S, Yoshikawa J. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol 1997;30:935-941.

    Google Scholar 

  71. Yokayama I, Monomura SI, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y, Omata M. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997;30:1472-1477.

    Google Scholar 

  72. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242.

    Google Scholar 

  73. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998;47:290-293.

    Google Scholar 

  74. Colwell JA. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:1011-1030.

    Google Scholar 

  75. Nishimoto Y, Miyazaki Y, Toki Y, Murakami R, Shinoda M, Fukushima A, Kanayama H. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: Elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol 1998;32:1624-1629.

    Google Scholar 

  76. Sobel BE. Acceleration of restenosis by diabetes: Pathogenetic implications. Circulation 2001;103:1185-1187.

    Google Scholar 

  77. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: A reconcilable paradox. Circulation 1999;99:2496-2498.

    Google Scholar 

  78. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-1535.

    Google Scholar 

  79. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies. J Diabetes Complications 2002;16:50-55.

    Google Scholar 

  80. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-574.

    Google Scholar 

  81. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-2516.

    Google Scholar 

  82. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.

    Google Scholar 

  83. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT investigators. Lancet 1998;352:87-92.

  84. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. The ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet 2000;356:2037-2044.

    Google Scholar 

  85. Nasser TK, Mohler ERI, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol 1995;18:609-614.

    Google Scholar 

  86. Levine GN, Kern MJ, Berger PB, Brown DL, Klein LW, Kereiakes DJ, Sanborn TA, Jacobs AK; American Heart Association Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003;139:123-136.

    Google Scholar 

  87. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.

    Google Scholar 

  88. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-182.

    Google Scholar 

  89. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.

    Google Scholar 

  90. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.

    Google Scholar 

  91. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 2003;289:553-558.

    Google Scholar 

  92. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high-and low-osmolality iodinated contrast media. Radiology 1993;188:171-178.

    Google Scholar 

  93. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ; Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.

    Google Scholar 

  94. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549-1558.

    Google Scholar 

  95. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-2484.

    Google Scholar 

  96. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.

  97. Cho L, Marso SP, Bhatt DL, Topol EJ. Optimizing percutaneous coronary revascularization in diabetic women: Analysis from the EPISTENT trial. J Women's Health Gend Med 2000;9:741-746.

    Google Scholar 

  98. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetics patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-2771.

    Google Scholar 

  99. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167.

    Google Scholar 

  100. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-535.

    Google Scholar 

  101. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 1999;138:S1-S5.

    Google Scholar 

  102. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet 2000;356:2037-2044.

    Google Scholar 

  103. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial, a randomized controlled trial. JAMA 2001;285:2468-2473.

    Google Scholar 

  104. O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, Gilchrist IC, Kleiman NS, Labinaz M, Madan M, Hafley GE, Califf RM, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287:618-621.

    Google Scholar 

  105. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. N Engl J Med 1998;339:436-443.

    Google Scholar 

  106. Theroux P, Alexander J Jr., Pharand C, Barr E, Snapinn S, Ghannam AF, Sax FL. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000;102:2466-2472.

    Google Scholar 

  107. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirulimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.

    Google Scholar 

  108. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: Drug-eluting stents: Part I. Circulation 2003;107:2274-2279.

    Google Scholar 

  109. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. N Engl J Med 2003;349:1315-1323.

    Google Scholar 

  110. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.

    Google Scholar 

  111. Silber S. Paclitaxel-eluting stents: Are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 2003;16:485-490.

    Google Scholar 

  112. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.

    Google Scholar 

  113. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The BARI Investigators. N Engl J Med 1996;335:217-225.

  114. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI) by treatment and diabetic status. The BARI investigators. J Am Coll Cardiol 2000;35:1122-1129.

  115. Detre KM, Lombardero MS, Brooks MM, Hardison RM, Holubkov R, Sopko G, Frye RL, Chaitman BR. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigators. N Engl J Med 2000;342:989-997.

    Google Scholar 

  116. Kip KE, Alderman EL, Bourassa MG, Brooks MM, Schwartz L, Holmes DR Jr, Califf RM, Whitlow PL, Chaitman BR, Detre KM. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: Bypass angioplasty revascularization investigation. Circulation 2002;105:1914-1920.

    Google Scholar 

  117. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.

    Google Scholar 

  118. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533-538.

    Google Scholar 

  119. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (The Stent or Surgery trial): A randomized controlled trial. The SOS Investigators. Lancet 2002;360:965-970.

  120. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.

  121. Mehta S, Yusuf S, Peters R, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.

    Google Scholar 

  122. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. CREDO Investigators. JAMA 2002;288:2411-2420.

    Google Scholar 

  123. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.

  124. Bhatt DL, Marso SP, Hirsch A, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with a history of diabetes mellitus. Am J Cardiol 2002;90:625-628.

    Google Scholar 

  125. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-1756.

    Google Scholar 

  126. Cleveland JC Jr., Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: Two paradoxes revisited. Circulation 1997;96:29-32.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

    Juhana Karha & Deepak L. Bhatt

Authors
  1. Juhana Karha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak L. Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karha, J., Bhatt, D.L. Percutaneous Coronary Intervention in Diabetics. Rev Endocr Metab Disord 5, 277–285 (2004). https://doi.org/10.1023/B:REMD.0000032417.33194.09

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:REMD.0000032417.33194.09

Search

Navigation